Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Fotagliptin (SAL067) in T2DM Patients Uncontrolled by Metformin
NCT05801627Phase 3Completed
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
- Start
- May 2020
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of fotagliptin in type 2 diabetes mellitus (T2DM), sponsored by Shenzhen Salubris Pharmaceuticals Co., Ltd.. Started May 2020; status: completed.
02
Drugs
fotagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05801627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05801627.